Spots Global Cancer Trial Database for Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Official Title: Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies
Study ID: NCT00288444
Study Description
Brief Summary: To determine the molecular interaction in tumor samples between docetaxel and lonafarnib.
Detailed Description: 1. To determine the safety and toxicity of intravenous docetaxel, administered on a weekly schedule (3 weeks out of 4), in combination with oral lonafarnib, administered on a daily schedule, in patients with locally advanced and metastatic solid tumor malignancies which are refractory to the standard of care. 2. To determine the pharmacokinetic interaction between docetaxel and lonafarnib. 3. To determine the molecular interaction in peripheral blood mononuclear cells between docetaxel and lonafarnib
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Contact Details
Name: John Kauh, MD
Affiliation: Emory University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
